NF-κB activation has been detected in the mucosa of patients with IBD and in murine colitis model, and inhibition of NF-κB with a specific p65 antisense oligonucleotide is effective in preventing experimental models of IBD and efficiently down-regulates cytokine production [45]. Here, NFKB1 is linked to inflammatory bowel disease.